Skip to main content
NCBI home page
Genitourinary Medicine logoLink to Genitourinary Medicine
. 1985 Aug;61(4):244–246. doi: 10.1136/sti.61.4.244

Susceptibility of different serovars of Chlamydia trachomatis to inactivation by normal human serum.

M F Osborn, A P Johnson, D Taylor-Robinson
PMCID: PMC1011821  PMID: 4018804

Abstract

The ability of a panel of normal human serum samples to inactivate 12 strains of Chlamydia trachomatis, each of a different serovar, was investigated. A wide range of antichlamydial activity was observed, with survival rates of C trachomatis varying from less than 1% in some experiments to 100% in others. The strain specificity of the anti-chlamydial activity exhibited by individual serum samples was not, however, related to the antigenic cross reactivity between serovars demonstrable by microimmunofluorescence testing, which suggested that type specific antigens were not predominantly involved in the inactivation process.

Full text

PDF
244

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Evans R. T., Taylor-Robinson D. Development and evaluation of an enzyme-linked immunosorbent assay (ELISA), using chlamydial group antigen, to detect antibodies, to Chlamydia trachomatis. J Clin Pathol. 1982 Oct;35(10):1122–1128. doi: 10.1136/jcp.35.10.1122. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Grayston J. T., Wang S. New knowledge of chlamydiae and the diseases they cause. J Infect Dis. 1975 Jul;132(1):87–105. doi: 10.1093/infdis/132.1.87. [DOI] [PubMed] [Google Scholar]
  3. Johnson A. P., Osborn M. F., Rowntree S., Thomas B. J., Taylor-Robinson D. A study of inactivation of Chlamydia trachomatis by normal human serum. Br J Vener Dis. 1983 Dec;59(6):369–372. doi: 10.1136/sti.59.6.369. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Newhall W. J., Batteiger B., Jones R. B. Analysis of the human serological response to proteins of Chlamydia trachomatis. Infect Immun. 1982 Dec;38(3):1181–1189. doi: 10.1128/iai.38.3.1181-1189.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Salari S. H., Ward M. E. Polypeptide composition of Chlamydia trachomatis. J Gen Microbiol. 1981 Apr;123(2):197–207. doi: 10.1099/00221287-123-2-197. [DOI] [PubMed] [Google Scholar]
  6. Taylor-Robinson D., Thomas B. J. The rôle of Chlamydia trachomatis in genital-tract and associated diseases. J Clin Pathol. 1980 Mar;33(3):205–233. doi: 10.1136/jcp.33.3.205. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Thomas B. J., Evans R. T., Hutchinson G. R., Taylor-Robinson D. Early detection of chlamydial inclusions combining the use of cycloheximide-treated McCoy cells and immunofluorescence staining. J Clin Microbiol. 1977 Sep;6(3):285–292. doi: 10.1128/jcm.6.3.285-292.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Thomas B. J., Reeve P., Oriel J. D. Simplified serological test for antibodies to Chlamydia trachomatis. J Clin Microbiol. 1976 Jul;4(1):6–10. doi: 10.1128/jcm.4.1.6-10.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Yong E. C., Klebanoff S. J., Kuo C. C. Toxic effect of human polymorphonuclear leukocytes on Chlamydia trachomatis. Infect Immun. 1982 Aug;37(2):422–426. doi: 10.1128/iai.37.2.422-426.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Genitourinary Medicine are provided here courtesy of BMJ Publishing Group

RESOURCES